VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to develop a rat liver model that will complement its existing NAMkind™ human liver platform and expand the Company’s liver toxicology capabilities.

The new model is designed to address a longstanding challenge in drug development: toxicity observed in rats does not always translate to humans.

VivoSim’s current human liver model is designed to identify human toxicity that may not appear in animal studies. The planned rat model would add the reverse capability, helping sponsors determine when an adverse finding in rats may be species-specific.